NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA®
December 31, 2020
LYON, France – NETRIS Pharma, a clinical-stage biopharmaceutical company developing therapeutics based on dependence receptor biology, today announced that the first patient has been dosed in its GYNet Phase 1b/II clinical study.
GYNet is a randomized, multicenter, open label Phase Ib/II study that will enroll up to 240 patients with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy. In the Phase1b part, the study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NP137 administered in combination with KEYTRUDA and/or chemotherapeutic agents. The Phase 2 part will assess the clinical activity of the combination in both tumor types. More information on GYNet study can be found at https://www.clinicaltrials.gov (NCT04652076).
Read more > http://www.netrispharma.com/netrispharma-firstpatient-gynet-keytruda/